Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Myelofibrosis Due to and Following Polycythemia Vera”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 0 results

Large-scale testing (Phase 3)Study completedNCT00934544
What this trial is testing

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 219
Testing effectiveness (Phase 2)Study completedNCT01901432
What this trial is testing

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

Who this might be right for
Polycythemia Vera
Italfarmaco 48
Testing effectiveness (Phase 2)Study completedNCT01340651
What this trial is testing

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Who this might be right for
Myelofibrosis
Incyte Corporation 41
Testing effectiveness (Phase 2)Ended earlyNCT04854096
What this trial is testing

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
NS Pharma, Inc. 7
Early research (Phase 1)Ended earlyNCT03373877
What this trial is testing

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more
Samus Therapeutics, Inc. 4
Testing effectiveness (Phase 2)Study completedNCT04217993
What this trial is testing

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis(Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 51
Testing effectiveness (Phase 2)Ended earlyNCT02718300
What this trial is testing

INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 74
Large-scale testing (Phase 3)Study completedNCT02101268
What this trial is testing

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Sierra Oncology LLC - a GSK company 156
Testing effectiveness (Phase 2)Active Not RecruitingNCT04446650
What this trial is testing

Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Who this might be right for
Primary Myelofibrosis
Bristol-Myers Squibb 31
Early research (Phase 1)Looking for participantsNCT07469891
What this trial is testing

PRT12396 in Participants With Select Myeloproliferative Neoplasms

Who this might be right for
Polycythemia Vera (PV)Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)+3 more
Prelude Therapeutics Incorporated 100
Not applicableLooking for participantsNCT06976918
What this trial is testing

Research Platform Myelofibrosis and Anemia

Who this might be right for
Primary MyelofibrosisSecondary MyelofibrosisPost-polycythemia Vera Myelofibrosis+4 more
iOMEDICO AG 200
Not applicableLooking for participantsNCT06073847
What this trial is testing

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Bristol-Myers Squibb 137
Testing effectiveness (Phase 2)Study completedNCT04884191
What this trial is testing

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost- Essential Thrombocythemia Myelofibrosis
CTI BioPharma 165
Large-scale testing (Phase 3)Study completedNCT01969838
What this trial is testing

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Sierra Oncology LLC - a GSK company 432
Early research (Phase 1)Ended earlyNCT03935555
What this trial is testing

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Samus Therapeutics, Inc. 11